Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children's Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
The PREIS School (International and European School of Perinatal, Neonatal and Reproductive Medicine), Firenze, Italy.
J Matern Fetal Neonatal Med. 2024 Dec;37(1):2390637. doi: 10.1080/14767058.2024.2390637. Epub 2024 Aug 18.
Antiphospholipid syndrome in neonates and children is a rare, but in some cases life-threatening condition with arterial and/or venous thrombosis and/or non-thrombotic neurological, skin, ophthalmological and other manifestations.
This review highlights the available information about the features of pediatric APS, including the rare catastrophic form, the differences between pediatric and adult APS, and the role of genetic thrombophilia in APS manifestation.
The clinical manifestations and treatment options for APS in children may differ from those in adults, and prescribing therapy can be challenging due to the unique clinical and morphological characteristics of the pediatric patient. Pediatric APS may be a predictor of the development of certain autoimmune diseases and classic manifestations of APS in adulthood, therefore, a revision of the existing criteria for the diagnosis and treatment of APS in children is necessary.
新生儿和儿童抗磷脂综合征是一种罕见但在某些情况下危及生命的疾病，其特征为动脉和/或静脉血栓形成以及/或非血栓性神经、皮肤、眼科和其他表现。
本综述强调了有关儿科抗磷脂综合征特征的现有信息，包括罕见的灾难性形式、儿科抗磷脂综合征与成人抗磷脂综合征之间的差异，以及遗传易栓症在抗磷脂综合征表现中的作用。
儿童抗磷脂综合征的临床表现和治疗选择可能与成人不同，由于儿科患者的独特临床和形态学特征，开具治疗方案可能具有挑战性。儿科抗磷脂综合征可能是某些自身免疫性疾病和成年后经典抗磷脂综合征表现的预测因素，因此，有必要修订现有的儿科抗磷脂综合征诊断和治疗标准。
